TDMS Study 89029-12 Pathology Tables
NTP STATISTICAL ANALYSIS OF PRIMARY TUMORS REPORT: PEIRPT08
LAB: Battelle Northwest MAGNETIC FIELDS + DMBA INITIATION PROMOTION DATE: 01/07/98
EXPERIMENT: 89029 TEST: 12 TIME: 16:02:40
TEST TYPE: SUBCHRON 90-DAY CAGES FROM 0000 TO LAST CAGE PAGE:
CONT: N01-ES-65397 ROUTE: MAGNETIC FIELDS NTP C#: 89029D
PATHOLOGIST: GRUMBEIN, S. CAS: EMF+DMBA
Rats(SPRAGUE-DAWLEY)
-----------------------------
FOR ALL DOSES THE TUMOR RATES IN THE FOLLOWING TISSUES/ORGANS ARE BASED ON NUMBER OF TISSUES EXAMINED.
IN OTHER TISSUES/ORGANS, RATES ARE BASED ON NUMBER OF ANIMALS NECROPSIED.
----------------
Adrenal Gland
Adrenal Medulla
Bone Marrow
Brain
Clitoral Gland
Clitoral/Preputial Gland
Epididymis
Heart
Islets, Pancreatic
Kidney
Liver
Lung
Nose
Ovary
Pancreas
Parathyroid Gland
Pituitary Gland
Preputial Gland
Prostate
Salivary Glands
Spleen
Testes
Thymus
Thyroid Gland
Urinary Bladder
NTP STATISTICAL ANALYSIS OF PRIMARY TUMORS REPORT: PEIRPT08
LAB: Battelle Northwest MAGNETIC FIELDS + DMBA INITIATION PROMOTION DATE: 01/07/98
EXPERIMENT: 89029 TEST: 12 TIME: 16:02:40
TEST TYPE: SUBCHRON 90-DAY CAGES FROM 0000 TO LAST CAGE PAGE:
CONT: N01-ES-65397 ROUTE: MAGNETIC FIELDS NTP C#: 89029D
PATHOLOGIST: GRUMBEIN, S. CAS: EMF+DMBA
SUMMARY OF STATISTICALLY SIGNIFICANT (P<=.05) RESULTS
IN THE ANALYSIS OF MAGNETIC FIELDS + DMBA INITIATION PROMOTIO
===============================================================
Female Rats
------------
Organ Morphology
----- ----------
Mammary Gland Carcinoma
Carcinoma or Adenoma
Fibroma, Fibroadenoma or Adenoma
Fibroma, Fibroadenoma, Carcinoma, or Adenoma
All Organs Leukemia: Lymphocytic, Monocytic, Mononuclear, or Undifferentiated
Benign Tumors
Malignant Tumors
Malignant and Benign Tumors
===============================================================
Date: 01/07/98 EXPERIMENT: 89029 TEST: 12 Page 1
Statistical Analysis of Primary Tumors in Rats(SPRAGUE-DAWLEY) - MAGNETIC FIELDS + DMBA INITIATION PROMOTIO
Terminal Sacrifice at 12 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 20 DMBA UNTREATD 50 HZ/1G 60 HZ/1G 50 HZ/5G |
| | CONTROL CONTROL 20 DMBA 20 DMBA 20 DMBA |
|=================================================================================================================================|
| |
|Mammary Gland |
| Adenoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # # |
|----------- | |
|OVERALL (a) | 2/100 (2%) 0/100 (0%) 1/100 (1%) 1/100 (1%) 0/100 (0%) |
|POLY-3 ADJUSTED (b)| 2.1% 0.0% 1.1% 1.0% 0.0% |
|TERMINAL (d) | 2/94 (2%) 0/100 (0%) 1/87 (1%) 1/95 (1%) 0/92 (0%) |
|FIRST INCIDENCE | 90 (T) --- 90 (T) 90 (T) --- |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.195N P=0.226N P=0.527N P=0.496N P=0.244N |
|POLY 3 | P=0.195N P=0.233N P=0.509N P=0.497N P=0.240N |
|POLY 1.5 | P=0.192N P=0.235N P=0.505N P=0.498N P=0.240N |
|POLY 6 | P=0.199N P=0.230N P=0.514N P=0.495N P=0.242N |
|LOGISTIC REGRESSION| P=0.195N (e) P=0.527N P=0.496N (e) |
|COCH-ARM / FISHERS | P=0.187N P=0.249N P=0.500N P=0.500N P=0.249N |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 20 DMBA UNTREATD 50 HZ/1G 60 HZ/1G 50 HZ/5G |
| | CONTROL CONTROL 20 DMBA 20 DMBA 20 DMBA |
|=================================================================================================================================|
| |
|Mammary Gland |
| Carcinoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # # |
|----------- | |
|OVERALL (a) | 92/100 (92%) 0/100 (0%) 86/100 (86%) 96/100 (96%) 96/100 (96%) |
|POLY-3 ADJUSTED (b)| 92.7% 0.0% 88.6% 96.0% 96.7% |
|TERMINAL (d) | 87/94 (93%) 0/100 (0%) 79/87 (91%) 91/95 (96%) 89/92 (97%) |
|FIRST INCIDENCE | 72 --- 73 64 65 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** P<0.001N** P=0.534 P=0.328 P=0.144 |
|POLY 3 | P<0.001 ** P<0.001N** P=0.222N P=0.238 P=0.168 |
|POLY 1.5 | P<0.001 ** P<0.001N** P=0.177N P=0.218 P=0.173 |
|POLY 6 | P<0.001 ** P<0.001N** P=0.290N P=0.256 P=0.166 |
|LOGISTIC REGRESSION| P<0.001 ** P<0.001N** P=0.201N P=0.206 P=0.161 |
|COCH-ARM / FISHERS | P<0.001 ** P<0.001N** P=0.129N P=0.186 P=0.186 |
|=================================================================================================================================|
Date: 01/07/98 EXPERIMENT: 89029 TEST: 12 Page 2
Statistical Analysis of Primary Tumors in Rats(SPRAGUE-DAWLEY) - MAGNETIC FIELDS + DMBA INITIATION PROMOTIO
Terminal Sacrifice at 12 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 20 DMBA UNTREATD 50 HZ/1G 60 HZ/1G 50 HZ/5G |
| | CONTROL CONTROL 20 DMBA 20 DMBA 20 DMBA |
|=================================================================================================================================|
| |
|Mammary Gland |
| Carcinoma or Adenoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # # |
|----------- | |
|OVERALL (a) | 93/100 (93%) 0/100 (0%) 86/100 (86%) 96/100 (96%) 96/100 (96%) |
|POLY-3 ADJUSTED (b)| 93.7% 0.0% 88.6% 96.0% 96.7% |
|TERMINAL (d) | 88/94 (94%) 0/100 (0%) 79/87 (91%) 91/95 (96%) 89/92 (97%) |
|FIRST INCIDENCE | 72 --- 73 64 65 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** P<0.001N** P=0.548N P=0.410 P=0.193 |
|POLY 3 | P<0.001 ** P<0.001N** P=0.148N P=0.337 P=0.251 |
|POLY 1.5 | P<0.001 ** P<0.001N** P=0.114N P=0.311 P=0.255 |
|POLY 6 | P<0.001 ** P<0.001N** P=0.202N P=0.359 P=0.249 |
|LOGISTIC REGRESSION| P<0.001 ** P<0.001N** P=0.134N P=0.295 P=0.238 |
|COCH-ARM / FISHERS | P<0.001 ** P<0.001N** P=0.083N P=0.269 P=0.269 |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 20 DMBA UNTREATD 50 HZ/1G 60 HZ/1G 50 HZ/5G |
| | CONTROL CONTROL 20 DMBA 20 DMBA 20 DMBA |
|=================================================================================================================================|
| |
|Mammary Gland |
| Fibroadenoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # # |
|----------- | |
|OVERALL (a) | 3/100 (3%) 0/100 (0%) 2/100 (2%) 1/100 (1%) 1/100 (1%) |
|POLY-3 ADJUSTED (b)| 3.1% 0.0% 2.1% 1.0% 1.0% |
|TERMINAL (d) | 3/94 (3%) 0/100 (0%) 2/87 (2%) 1/95 (1%) 1/92 (1%) |
|FIRST INCIDENCE | 90 (T) --- 90 (T) 90 (T) 90 (T) |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.263N P=0.112N P=0.535N P=0.303N P=0.315N |
|POLY 3 | P=0.260N P=0.117N P=0.512N P=0.304N P=0.310N |
|POLY 1.5 | P=0.256N P=0.119N P=0.507N P=0.305N P=0.309N |
|POLY 6 | P=0.264N P=0.115N P=0.518N P=0.302N P=0.312N |
|LOGISTIC REGRESSION| P=0.263N (e) P=0.535N P=0.303N P=0.315N |
|COCH-ARM / FISHERS | P=0.251N P=0.123N P=0.500N P=0.311N P=0.311N |
|=================================================================================================================================|
Date: 01/07/98 EXPERIMENT: 89029 TEST: 12 Page 3
Statistical Analysis of Primary Tumors in Rats(SPRAGUE-DAWLEY) - MAGNETIC FIELDS + DMBA INITIATION PROMOTIO
Terminal Sacrifice at 12 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 20 DMBA UNTREATD 50 HZ/1G 60 HZ/1G 50 HZ/5G |
| | CONTROL CONTROL 20 DMBA 20 DMBA 20 DMBA |
|=================================================================================================================================|
| |
|Mammary Gland |
| Fibroma, Fibroadenoma or Adenoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # # |
|----------- | |
|OVERALL (a) | 5/100 (5%) 0/100 (0%) 3/100 (3%) 2/100 (2%) 1/100 (1%) |
|POLY-3 ADJUSTED (b)| 5.1% 0.0% 3.2% 2.0% 1.0% |
|TERMINAL (d) | 5/94 (5%) 0/100 (0%) 3/87 (3%) 2/95 (2%) 1/92 (1%) |
|FIRST INCIDENCE | 90 (T) --- 90 (T) 90 (T) 90 (T) |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.128N P=0.030N* P=0.402N P=0.217N P=0.112N |
|POLY 3 | P=0.125N P=0.032N* P=0.373N P=0.217N P=0.108N |
|POLY 1.5 | P=0.122N P=0.033N* P=0.368N P=0.219N P=0.107N |
|POLY 6 | P=0.129N P=0.031N* P=0.382N P=0.216N P=0.109N |
|LOGISTIC REGRESSION| P=0.128N (e) P=0.402N P=0.217N P=0.112N |
|COCH-ARM / FISHERS | P=0.118N P=0.030N* P=0.360N P=0.222N P=0.106N |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 20 DMBA UNTREATD 50 HZ/1G 60 HZ/1G 50 HZ/5G |
| | CONTROL CONTROL 20 DMBA 20 DMBA 20 DMBA |
|=================================================================================================================================|
| |
|Mammary Gland |
| Fibroma, Fibroadenoma, Carcinoma, or Adenoma |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # # |
|----------- | |
|OVERALL (a) | 93/100 (93%) 0/100 (0%) 86/100 (86%) 96/100 (96%) 96/100 (96%) |
|POLY-3 ADJUSTED (b)| 93.7% 0.0% 88.6% 96.0% 96.7% |
|TERMINAL (d) | 88/94 (94%) 0/100 (0%) 79/87 (91%) 91/95 (96%) 89/92 (97%) |
|FIRST INCIDENCE | 72 --- 73 64 65 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** P<0.001N** P=0.548N P=0.410 P=0.193 |
|POLY 3 | P<0.001 ** P<0.001N** P=0.148N P=0.337 P=0.251 |
|POLY 1.5 | P<0.001 ** P<0.001N** P=0.114N P=0.311 P=0.255 |
|POLY 6 | P<0.001 ** P<0.001N** P=0.202N P=0.359 P=0.249 |
|LOGISTIC REGRESSION| P<0.001 ** P<0.001N** P=0.134N P=0.295 P=0.238 |
|COCH-ARM / FISHERS | P<0.001 ** P<0.001N** P=0.083N P=0.269 P=0.269 |
|=================================================================================================================================|
Date: 01/07/98 EXPERIMENT: 89029 TEST: 12 Page 4
Statistical Analysis of Primary Tumors in Rats(SPRAGUE-DAWLEY) - MAGNETIC FIELDS + DMBA INITIATION PROMOTIO
Terminal Sacrifice at 12 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 20 DMBA UNTREATD 50 HZ/1G 60 HZ/1G 50 HZ/5G |
| | CONTROL CONTROL 20 DMBA 20 DMBA 20 DMBA |
|=================================================================================================================================|
| |
|All Organs |
| Leukemia: Lymphocytic, Monocytic, Mononuclear, or |
| Undifferentiated |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # # |
|----------- | |
|OVERALL (a) | 15/100 (15%) 0/100 (0%) 16/100 (16%) 12/100 (12%) 10/100 (10%) |
|POLY-3 ADJUSTED (b)| 15.1% 0.0% 16.1% 12.2% 10.1% |
|TERMINAL (d) | 11/94 (12%) 0/100 (0%) 6/87 (7%) 11/95 (12%) 5/92 (5%) |
|FIRST INCIDENCE | 58 --- 49 89 65 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.411 P<0.001N** P=0.442 P=0.333N P=0.216N |
|POLY 3 | P=0.422 P<0.001N** P=0.497 P=0.352N P=0.202N |
|POLY 1.5 | P=0.428 P<0.001N** P=0.499 P=0.347N P=0.200N |
|POLY 6 | P=0.414 P<0.001N** P=0.493 P=0.358N P=0.205N |
|LOGISTIC REGRESSION| P=0.465N P<0.001N** P=0.373N P=0.393N P=0.133N |
|COCH-ARM / FISHERS | P=0.439 P<0.001N** P=0.500 P=0.340N P=0.196N |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 20 DMBA UNTREATD 50 HZ/1G 60 HZ/1G 50 HZ/5G |
| | CONTROL CONTROL 20 DMBA 20 DMBA 20 DMBA |
|=================================================================================================================================|
| |
|All Organs |
| Benign Tumors |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # # |
|----------- | |
|OVERALL (a) | 5/100 (5%) 0/100 (0%) 3/100 (3%) 2/100 (2%) 1/100 (1%) |
|POLY-3 ADJUSTED (b)| 5.1% 0.0% 3.2% 2.0% 1.0% |
|TERMINAL (d) | 5/94 (5%) 0/100 (0%) 3/87 (3%) 2/95 (2%) 1/92 (1%) |
|FIRST INCIDENCE | 90 (T) --- 90 (T) 90 (T) 90 (T) |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.128N P=0.030N* P=0.402N P=0.217N P=0.112N |
|POLY 3 | P=0.125N P=0.032N* P=0.373N P=0.217N P=0.108N |
|POLY 1.5 | P=0.122N P=0.033N* P=0.368N P=0.219N P=0.107N |
|POLY 6 | P=0.129N P=0.031N* P=0.382N P=0.216N P=0.109N |
|LOGISTIC REGRESSION| P=0.128N (e) P=0.402N P=0.217N P=0.112N |
|COCH-ARM / FISHERS | P=0.118N P=0.030N* P=0.360N P=0.222N P=0.106N |
|=================================================================================================================================|
Date: 01/07/98 EXPERIMENT: 89029 TEST: 12 Page 5
Statistical Analysis of Primary Tumors in Rats(SPRAGUE-DAWLEY) - MAGNETIC FIELDS + DMBA INITIATION PROMOTIO
Terminal Sacrifice at 12 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 20 DMBA UNTREATD 50 HZ/1G 60 HZ/1G 50 HZ/5G |
| | CONTROL CONTROL 20 DMBA 20 DMBA 20 DMBA |
|=================================================================================================================================|
| |
|All Organs |
| Malignant Tumors |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # # |
|----------- | |
|OVERALL (a) | 93/100 (93%) 0/100 (0%) 92/100 (92%) 96/100 (96%) 96/100 (96%) |
|POLY-3 ADJUSTED (b)| 93.0% 0.0% 92.0% 96.0% 96.7% |
|TERMINAL (d) | 87/94 (93%) 0/100 (0%) 79/87 (91%) 91/95 (96%) 89/92 (97%) |
|FIRST INCIDENCE | 58 --- 49 64 65 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** P<0.001N** P=0.208 P=0.413 P=0.204 |
|POLY 3 | P<0.001 ** P<0.001N** P=0.500N P=0.268 P=0.193 |
|POLY 1.5 | P<0.001 ** P<0.001N** P=0.500N P=0.268 P=0.217 |
|POLY 6 | P<0.001 ** P<0.001N** P=0.500N P=0.268 P=0.176 |
|LOGISTIC REGRESSION| P<0.001 ** (e) (e) (e) P=0.257 |
|COCH-ARM / FISHERS | P<0.001 ** P<0.001N** P=0.500N P=0.269 P=0.269 |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 20 DMBA UNTREATD 50 HZ/1G 60 HZ/1G 50 HZ/5G |
| | CONTROL CONTROL 20 DMBA 20 DMBA 20 DMBA |
|=================================================================================================================================|
| |
|All Organs |
| Malignant and Benign Tumors |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # # |
|----------- | |
|OVERALL (a) | 94/100 (94%) 0/100 (0%) 92/100 (92%) 96/100 (96%) 96/100 (96%) |
|POLY-3 ADJUSTED (b)| 94.0% 0.0% 92.0% 96.0% 96.7% |
|TERMINAL (d) | 88/94 (94%) 0/100 (0%) 79/87 (91%) 91/95 (96%) 89/92 (97%) |
|FIRST INCIDENCE | 58 --- 49 64 65 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** P<0.001N** P=0.257 P=0.499 P=0.264 |
|POLY 3 | P<0.001 ** P<0.001N** P=0.391N P=0.373 P=0.284 |
|POLY 1.5 | P<0.001 ** P<0.001N** P=0.391N P=0.373 P=0.314 |
|POLY 6 | P<0.001 ** P<0.001N** P=0.391N P=0.373 P=0.261 |
|LOGISTIC REGRESSION| P<0.001 ** (e) (e) (e) P=0.360 |
|COCH-ARM / FISHERS | P<0.001 ** P<0.001N** P=0.391N P=0.374 P=0.374 |
|=================================================================================================================================|
(a) Number of tumor-bearing animals / number of animals examined at site.
(b) Poly-3 adjusted lifetime tumor incidence.
(d) Observed incidence at terminal kill.
(f) Beneath the control incidence are the P-values associated with the trend
test. Beneath the dosed group incidence are the P-values corresponding to
pairwise comparisons between the controls and that dosed group. The life
table analysis regards tumors in animals dying prior to terminal kill as
being (directly or indirectly) the cause of death.
Logistic regression is an alternative
method for analyzing the incidence of non-fatal tumors. The Cochran-Armitage
and Fishers exact tests compare directly the overall incidence rates
For all tests a negative trend is indicated by N
(e) Value of Statistic cannot be computed.
(I) Interim sacrifice
(T) Terminal sacrifice
# Tumor rates based on number of animals necropsied.
* To the right of any statistical result, indicates significance at (P<=0.05).
** To the right of any statistical result, indicates significance at (P<=0.01).